Key facts
- It has raised $14.2M; the latest was Early Stage VC ($14.2M) in Dec 2025.
- Notable investors include IDG Capital, Puhua Capital, Suzhou Guofa Venture Capital, Leader Venture Capital, Shanghai Healthcare Capital — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Humatrix Medical
- ·The full record, as it builds
Funding rounds
No funding rounds for Humatrix Medical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Humatrix Medical
Developer of tissue engineering and regenerative medical technology designed for early-stage surgeries to treat heart diseases. The company offers development and produces allogeneic small-caliber tissue-engineered blood vessels for chronic renal failure dialysis vascular access, lower extremity arterial trauma vascular replacement, lower extremity atherosclerosis and coronary heart disease bypass surgery, thereby providing support for clinical research and innovated medical technology for cardiac medicine.
- Sector
- Healthcare
- HQ
- Suzhou, China
- Founded
- 2021
- Website
- humatrix-medical.com/
- Ownership
- Privately Held (backing)
Humatrix Medical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Humatrix Medical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Humatrix Medical in its N-PORT filings yet. We sweep new filings monthly.